H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $64 from $62 and keeps a Buy rating on the shares following the Q3 report. The firm says several key clinical data disclosures are anticipated in the coming months.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Reports Q3 2024 Results and Progress
- Revolution Medicines reports Q3 EPS (94c), consensus (89c)
- Revolution Medicines price target raised to $62 from $56 at H.C. Wainwright
- Revolution Medicines price target raised to $82 from $72 at Guggenheim
- Revolution Medicines price target raised to $60 from $55 at Oppenheimer